Skip to main content
Fig. 4 | Cardiovascular Diabetology

Fig. 4

From: Worldwide inertia to the use of cardiorenal protective glucose-lowering drugs (SGLT2i and GLP-1 RA) in high-risk patients with type 2 diabetes

Fig. 4

Savings to healthcare costs and resource utilisation with SGLT2i. a Savings across US insured populations with T2D. Two-year interim data from the EMPRISE real-world evidence study has measured the cost of care and healthcare resource utilisation for new initiators of empagliflozin vs DPP-4i in two commercial claims databases plus Medicare patients between August 2014 and September 2016, with an average of 5.4 months follow-up. Healthcare resource utilisation data were available for 17,549 patients in each arm matched 1:1 by propensity scoring, and showed ≥ 20% reductions in the numbers of hospitalisations and ER visits with empagliflozin per member per year (PMPY) [125]. Cost data were available for 2928 patients in each arm matched 1:1 by propensity scoring, and showed substantial savings with empagliflozin across the full cohort [126]. A model based on data from the CREDENCE renal outcomes study estimated that the total cost saving for a US insured population with T2D and CKD would be nearly $2000 PMPY when adding canagliflozin to standard of care [100]. b Savings per affected patient in the US, UK and Germany. Cost data from the US [100, 103], UK [101, 127] and Germany [102] showing the healthcare expenditure associated with HF and CKD. As expected, costs for the US are notably higher than in Europe; however, even in the UK and Germany expenditure is substantial

Back to article page
\